Edition:
United Kingdom

Intersect Ent Inc (XENT.OQ)

XENT.OQ on NASDAQ Stock Exchange Global Market

30.84USD
10 Dec 2018
Change (% chg)

$0.00 (+0.00%)
Prev Close
$30.84
Open
$30.65
Day's High
$31.17
Day's Low
$30.38
Volume
79,929
Avg. Vol
93,811
52-wk High
$42.90
52-wk Low
$25.15

Latest Key Developments (Source: Significant Developments)

Intersect ENT Inc Reports Qtrly Loss Per Share $0.14
Wednesday, 1 Aug 2018 

Aug 1 (Reuters) - Intersect Ent Inc ::TOTAL REVENUE GREW TO $26.3 MILLION FOR Q2 2018 COMPARED TO $24.0 MILLION FOR SAME PERIOD OF 2017.EXPECTS TO ACHIEVE Q3 REVENUE IN RANGE OF $23.8 TO $24.3 MILLION.QTRLY LOSS PER SHARE $0.14.SEES FULL YEAR REVENUE BETWEEN $106 MILLION TO $109 MILLION.EXPECTS Q3 AND FULL YEAR GROSS MARGIN OF ABOUT 80%.Q2 EARNINGS PER SHARE VIEW $-0.17, REVENUE VIEW $28.1 MILLION -- THOMSON REUTERS I/B/E/S.FY2018 REVENUE VIEW $116.3 MILLION -- THOMSON REUTERS I/B/E/S.  Full Article

Intersect ENT Reports Preliminary Q4 And Year 2017 Revenue
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Intersect ENT Inc ::INTERSECT ENT REPORTS PRELIMINARY Q4 AND YEAR 2017 REVENUE.SEES FY 2018 REVENUE $111 MILLION TO $116 MILLION.SEES Q1 2018 REVENUE $23.2 MILLION TO $23.7 MILLION.SEES FY 2017 REVENUE $96.1 MILLION TO $96.3 MILLION.SEES FY 2018 REVENUE UP 15 TO 20 PERCENT.SEES Q4 2017 REVENUE $29.3 MILLION TO $29.5 MILLION.- CO CONTINUES TO EXPECT TO LAUNCH SINUVA COMMERCIALLY IN Q2 OF 2018.Q4 EARNINGS PER SHARE VIEW $-0.17, REVENUE VIEW $27.7 MILLION -- THOMSON REUTERS I/B/E/S.FY2018 REVENUE VIEW $113.8 MILLION -- THOMSON REUTERS I/B/E/S.FY2017 REVENUE VIEW $94.5 MILLION -- THOMSON REUTERS I/B/E/S.  Full Article

‍James Flynn​ reports 5.92 pct passive stake in Intersect ENT
Thursday, 16 Nov 2017 

Nov 16 (Reuters) - Intersect Ent Inc ::‍James Flynn​ reports 5.92 percent passive stake in Intersect ENT as of Nov 6 - SEC filing.  Full Article

FDA performs pre-approval inspection of Intersect ENT's menlo park facility
Monday, 6 Nov 2017 

Nov 6 (Reuters) - Intersect ENT Inc :FDA performs pre-approval inspection of Intersect ENT's menlo park facility.Intersect ENT Inc - ‍FDA has set a pdufa target action date of January 7, 2018​.Intersect ENT Inc - ‍at conclusion of inspection, FDA issued a form 483 with four inspectional observations​.Intersect ENT Inc - does not expect inspectional observations to impact timeline for a decision from FDA on approval of sinuva implant​.  Full Article

Intersect ENT Inc reports Q3 revenue $22.3 million
Thursday, 2 Nov 2017 

Nov 2 (Reuters) - Intersect ENT Inc :Intersect ENT Inc reports third quarter 2017 results.Q3 revenue $22.3 million versus I/B/E/S view $21.5 million.Sees q4 2017 revenue $27.3 million to $27.8 million.Intersect ENT Inc - ‍outlook for 2017 gross margin continues to be about 84%​.Intersect ENT Inc - ‍for full year 2017 expects revenue in range of $94.1-$94.6 million​.  Full Article